ceptarisceptaris Companyceptaris Investigational Drugceptaris Newsceptaris Contact Us  
       
       
   
 
 

 

 


Ceptaris, a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.

Based upon results of a recently completed trial, Ceptaris intends to file a new drug application (NDA) with the Food and Drug Administration (FDA) in 2011. If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Ceptaris has augmented its management team with the addition of a number of experienced pharmaceutical executives as it approaches regulatory filing and potential commercialization of mechlorethamine gel.
 

 

 

 

 


HOME
Introduction
Legal Notices and Disclaimers
Privacy Policy
Sitemap
COMPANY
Introduction
Management
Board of Directors
Investors
INVESTIGATIONAL DRUG
Mechlorethamine Gel
NEWS
Top News
RSS Feed
CONTACT US
General Inquiries
Address and Map
Business Development
Media

 
   
   
   
   
         
print page